Decreased paraoxonase 1 (PON1) lactonase activity in hemodialyzed and renal transplanted patients. A novel cardiovascular biomarker in end-stage renal disease

Nephrology Dialysis Transplantation

Volumn 27, Issue 7, 2012, Pages 2866-2872

  Sztanek, Ferenc ^a   Seres, Ildikó ^a   Harangi, Mariann ^a   Lócsey, Lajos ^a   Padra, János ^a   Paragh, György J R ^b   Asztalos, László ^a   Parah, György ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b WEISS MEMORIAL HOSPITAL   (United States)

Author keywords

asymmetric dimethylarginine; chronic renal failure; lactonase; paraoxonase; renal transplantation

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; AZATHIOPRINE; CYCLOSPORIN; CYSTATIN C; GLUCONOLACTONASE; HOMOCYSTEINE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; N(G),N(G) DIMETHYLARGININE; PARAOXON; TACROLIMUS; THIOBUTYROLACTONE DERIVATIVE;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; DISEASE MARKER; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ENZYME SUBSTRATE COMPLEX; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; OXIDATIVE STRESS; POPULATION RESEARCH; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK ASSESSMENT;

ARYLDIALKYLPHOSPHATASE; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PROGNOSIS; RENAL DIALYSIS; RISK FACTORS;

EID: 84864413088     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfr753     Document Type: Article

References (34)

1. Zoccali C, Mallamaci F, Tripepi G. Inflammatory proteins as predictors of cardiovascular disease in patients with end-stage renal disease. Nephrol Dial Transplant 2004; 19Suppl 5V67-V72.
2. Okubo K, Hayashi K, Wakino S et al. Role of asymmetrical dimethylarginine in renal microvascular endothelial dysfunction in chronic renal failure with hypertension. Hypertens Res 2005; 28: 181-189.
3. Rozenberg O, Rosenblat M, Coleman R et al. Paraoxonase (PON1) deficiency is associated with increased macrophage oxidative stress: studies in PON1-knockout mice. Free Radic Biol Med 2003; 34: 774-784.
4. Beltowski J, Wójcicka G, Jamroz A. Leptin decreases plasma paraoxonase 1 (PON1) activity and induces oxidative stress: the possible novel mechanism for proatherogenic effect of chronic hyperleptinemia. Atherosclerosis 2003; 170: 21-29.
5. Senti M, Tomás M, Elosual R et al. The paraoxonase-1 codon 192 polymorphism is associated with fasting total cholesterol and LDLcholesterol concentrations only in postmenopausal women. The REGICOR study. Clin Chem Lab Med 2002; 40: 677-683.
6. Perla-Kaján J, Jakubowski H. Paraoxonase 1 protects against protein N-homocysteinylation in humans. FASEB J 2010; 24: 931-936.
7. Jakubowski H. The role of paraoxonase 1 in the detoxification of homocysteine thiolactone. Adv Exp Med Biol 2010; 660: 113-127.
8. Gugliucci A, Kinugasa E, Kotani K et al. Serum paraoxonase 1 (PON1) lactonase activity is lower in end-stage renal disease patients than in healthy control subjects and increases after hemodialysis. Clin Chem Lab Med 2011; 49: 61-67.
9. Domagała TB, Łacinski M, Trzeciak WH et al. The correlation of homocysteine-thiolactonase activity of the paraoxonase (PON1) protein with coronary heart disease status. Cell Mol Biol (Noisy-legrand) 2006; 52: 4-10.
10. Lakshman MR, Gottipati CS, Narasimhan SJ et al. Inverse correlation of serum paraoxonase and homocysteine thiolactonase activities and antioxidant capacity of high-density lipoprotein with the severity of cardiovascular disease in persons with type 2 diabetes mellitus. Metabolism 2006; 55: 1201-1206.
11. Kosaka T, Yamaguchi M, Motomura T et al. Investigation of the relationship between atherosclerosis and paraoxonase or homocysteine thiolactonase activity in patients with type 2 diabetes mellitus using a commercially available assay. Clin Chim Acta 2005; 359: 156-162.
12. Lacinski M, Skorupski W, Cieslinski A et al. Determinants of homocysteine-thiolactonase activity of the paraoxonase-1 (PON1) protein in humans. Cell Mol Biol (Noisy-le-grand) 2004; 50: 885-893.
13. Varga Z, Paragh G, Seres I et al. Hyperleptinemia is not responsible for decreased paraoxonase activity in hemodialysis patients. Nephron Clin Pract 2006; 103: c114-c120.
14. Matsuguma K, Ueda S, Yamagishi S et al. Molecular mechanism for elevation of asymmetric dimethylarginine and its role for hypertension in chronic kidney disease. J Am Soc Nephrol 2006; 17: 2176-2183.
15. Bełtowski J, Kedra A. Asymmetric dimethylarginine (ADMA) as a target for pharmacotherapy. Pharmacol Rep 2006; 58: 159-178.
16. Soveri I, Lind L, Wikstrom B et al. Improvement in central arterial pressure waveform during hemodialysis is related to a reduction in asymmetric dimethylarginine (ADMA) levels. Nephron Clin Pract 2007; 106: c180-c186.
17. Yilmaz MI, Saglam M, Caglar K et al. Endothelial functions improve with decrease in asymmetric dimethylarginine (ADMA) levels after renal transplantation. Transplantation 2005; 80: 1660-1666.
18. Paragh G, Asztalos L, Seres I et al. Serum paraoxonase activity changes in uremic and kidney-transplanted patients. Nephron 1999; 83: 126-131.
19. Gan KN, Smolen A, Eckerson HW et al. Purification of human serum paraoxonase/arylesterase. Evidence for one esterase catalyzing both activities. Drug Metab Dispos 1991; 19: 100-106.
20. Ellman GL, Courtney KD, Andres VJ et al. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 1961; 7: 88-95.
21. Pocsai Z, Toth Z, Paragh G et al. Rapid genotyping of paraoxonase 55 and 192 mutations by melting point analysis using real time PCR technology. Clin Chim Acta 2003; 33: 231-236.
22. Paragh G, Seres I, Harangi M et al. Discordance in human paraoxonase-1 gene between phenotypes and genotypes in chronic kidney disease. Nephron Clin Pract 2009; 113: c46-c53.
23. Akhmedova SN, Yakimovsky AK, Schwartz EI. Paraoxonase 1 Met-Leu 54 polymorphism is associated with Parkinson's disease. J Neurol Sci 2001; 184: 179-182.
24. Rainwater DL, Rutherford S, Dyer TD et al. Determinants of variation in human serum paraoxonase activity. Heredity 2009; 102: 147-154.
25. Draganov DI, Teiber JF, Speelman A et al. Human paraoxonases (PON1, PON2 and PON3) are lactonases with overlaping and distinct substrate specificities. J Lipid Res 2005; 46: 1239-1247.
26. Paragh G, Seres I, Balogh Z et al. The serum paraoxonase activity in patients with chronic renal failure and hyperlipidemia. Nephron 1998; 80: 166-170.
27. Hojs R, Bevc S, Ekart R et al. Serum cystatin C as an endogenous marker of renal function in patients with chronic kidney disease. Ren Fail 2008; 30: 181-186.
28. Böger RH, Bode-Böger SM, Frölich JC. The L-arginine-nitric oxide pathway: role in atherosclerosis and therapeutic implications. Atherosclerosis 1996; 127: 1-11.
29. Baylis C. Arginine, arginine analogs and nitric oxide production in chronic kidney disease. Nat Clin Pract Nephrol 2006; 2: 209-220.
30. Sydow K, Münzel T. ADMA and oxidative stress. Atheroscler Suppl 2003; 4: 41-51.
31. Zoccali C, Bode-Böger S, Mallamaci F et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 2001; 358: 2113-2117.
32. Gupta A, Robinson K. Hyperhomocysteinaemia and end stage renal disease. J Nephrol 1997; 10: 77-84.
33. Kerkeni M, Addad F, Chauffert M et al. Hyperhomocysteinemia, paraoxonase activity and risk of coronary artery disease. Clin Biochem 2006; 39: 821-825.
34. Varga E, Seres I, Harangi M et al. Serum cystatin C is a determinant of paraoxonase activity in hemodialyzed and renal transplanted patients. Dis Markers 2009; 26: 141-148.